Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
Coherus’ Acquisition of Surface Oncology
Quest Diagnostics’ Acquisition of Haystack Oncology
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Terreno Realty’s $359.4 Million Public Offering
Goodwin Procter advised Terreno Realty Corporation on the deal. Terreno Realty Corporation (NYSE: TRNO) announced its underwritten public offering of 5,750,000 shares of its common stock at...
Sun Pharmaceutical’s $576 Million Acquisition of Concert Pharmaceuticals
Davis Polk advised Sun Pharmaceutical, and Goodwin Procter advised Concert Pharmaceuticals. Sun Pharmaceutical Industries Limited announced its acquisition of Concert Pharmaceuticals Inc., through a tender offer for an...
Carlyle and Abingworth’s $170 Million Non-dilutive Financing of Opthea
Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...
Intermediate Capital Group’s Fundraising of European Corporate Fund
Goodwin advised Intermediate Capital Group on the deal. Intermediate Capital Group announced the structuring and fundraising of its eighth European Corporate fund. The Fund held a final...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Enfusion’s $367 Million IPO
Goodwin advised Enfusion on the deal, while Davis Polk advised the representatives of the several underwriters. Enfusion, Inc. completed its initial public offering of 21,562,500 shares...
Forge Global’s $2 Billion Merger with Motive Capital Corp
Goodwin Procter advised Forge Global on the deal. Forge Global announced its definitive merger agreement with Motive Capital Corp (NYSE: MOTV.U) sponsored by affiliates of Motive Partners....
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....
Xeris Pharmaceuticals’ Acquisition of Strongbridge Biopharma
Skadden, Arps, Slate, Meagher & Flom, LLP and Arthur Cox LLP advised Strongbridge, while Goodwin Procter LLP and A&L Goodbody LLP advised Xeris on the deal....